drugset / Trial / NCT01302067

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

NCT01302067

Phase 4 Completed 2012 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower dose. The study also assesses the side effects and safety of the two doses.

Timeline

Start
2011-05
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral

Indications